Clinical Trials

Other solid neoplasmThoracic

Carcinoma, Non-Small-Cell Lung

NCT04413227 2020-06-02

A Phase Ib Study With Pegylated Recombinant Human Endostatin in Advanced / Metastatic NSCLC or Other Solid Tumors

Phase 1 Unknown

30 enrolled

NSCLC

NCT04115410 2020-05-28

PD-1 Immune Checkpoint Inhibitors and Immune-Related Adverse Events: a Cohort Study

Unknown

4,724 enrolled

Carcinoma, Non-Small-Cell Lung

NCT02076477 2020-03-17

OITROLC

420 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03624309 2020-01-07

Anlotinib Plus Docetaxel for the Treatment of EGFR Wild-type Advanced Non-small-cell Lung Cancer

84 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04023617 2019-07-17

A Study of Nivolumab +/- Docetaxel in Patients Previously Treated With Advanced or Metastatic NSCLC

72 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03944980 2019-06-14

Study of Chemotherapy Combination With Autologous Cell Immunotherapy in the Advanced Lung Cancer

146 enrolled

IIIB/IIIC/IV Lung Cancer

NCT03726736 2019-06-07

ACWDVDFPTAN

Phase 1/2 Unknown

97 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03799601 2019-01-10

ALTER-L013

Phase 4 Unknown

45 enrolled

NSCLC

NCT03732001 2018-11-28

ALTER-L024

Carcinoma, Non-Small-Cell Lung

NCT03750916 2018-11-26

ACDFNSNSCLC

46 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03735264 2018-11-08

ACDFNSCLC

46 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03706703 2018-10-17

Rh-Endostatin (Endostar®) Continuous Intravenous Infusion

50 enrolled

Lung Neoplasms

NCT03703596 2018-10-12

Anlotinib Versus Docetaxel as the Second-line Treatment in EGFR Wild Type Patients With Advanced NSCLC

88 enrolled

Lung Neoplasms

NCT03407300 2018-09-13

A Safety and Efficacy Trial of Docetaxel With or Without XH1 in Non-small Cell Lung Cancer (NSCLC) Patients

Carcinoma, Non-Small-Cell Lung

NCT03654027 2018-08-31

Anlotinib Plus Docetaxel for the Treatment of EGFR/ALK/ROS1 Mutation-negative Advanced Nonsquamous NSCLC

84 enrolled

Carcinoma, Non-Small-Cell Lung

NCT02450656 2018-08-27

M14AFS

Phase 1/2 Unknown

320 enrolled

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT03566576 2018-06-25

Phase I Study of the Combination of Anlotinib With Pemetrexed or Docetaxel

Phase NA Unknown

18 enrolled

Non-squamous Non-small Cell Lung Cancer

NCT02884479 2018-04-25

An Open-Label Phase I/II Clinical Study of PT-112 in Combination With Docetaxel in Subjects With Advanced Solid Tumor in a Phase I Dose Escalation Study and in Subjects With Non-Small Cell Lung Cancer (NSCLC) in a Phase II Dose Confirmation Study

Phase 1/2 Unknown

75 enrolled

Carcinoma, Non-Small-Cell Lung

NCT02134990 2018-04-18

Oshadi D and Oshadi R in Combination With Docetaxel, as 2nd Line Therapy for Metastatic Non Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

NCT03416231 2018-01-31

Apatinib Plus Docetaxel in Advanced Non-squamous Non-small Cell Lung Cancer(NSCLC)

NSCLC

NCT03411967 2018-01-26

Apatinib in Combination With Docetaxel for Patients With Advanced NSCLC

Lung Neoplasms

NCT03269162 2017-09-14

Postoperative NSCLC Treated With Integrated Medicine Base on Circulating Tumor Cell Detection

144 enrolled

Phase EARLY_PHASE1 Unknown

NSCLC

NCT02568033 2017-01-31

Stereotactic Radiosurgery and Systemic Dose Chemotherapy for Locally Advanced Lung Cancer

22 enrolled

Carcinoma, Non-Small-Cell Lung

NCT02787473 2016-11-25

A Study of Pemetrexed Plus Cisplatin With Concurrent Radiation Therapy Followed by Docetaxel Consolidation in Patients With Inoperable Squamous Cell Lung Cancer

54 enrolled

Squamous Cell Lung Cancer

NCT01771289 2016-09-27

Neoadjuvant Concurrent Chemoradiation With Weekly Docetaxel/Cisplatin for Resectable IIIA-N2 NSCLC

50 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT01803503 2016-06-22

Docetaxel With or Without Low-dose, Short Course Sunitinib in Refractory Solid Tumors

BreastGastrointestinalGenitourinaryThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Prostatic Neoplasms, Stomach Neoplasms

NCT02780778 2016-05-23

Apatinib Plus Docetaxel as 2nd Line Treatment in Patients With Advanced Non-squamous and Non-small Cell Lung Cancer

Phase 2/3 Unknown

Carcinoma, Non-Small-Cell Lung

NCT02031601 2016-03-29

TCL-1

Phase 4 Unknown

250 enrolled

Carcinoma, Non-Small-Cell Lung

NCT02691871 2016-02-25

Apatinib Plus Docetaxel as 2nd Line Treatment in Patients With Advanced Lung Adenocarcinoma Harboring Wild-type EGFR

Phase 1 Unknown

Adenocarcinoma of Lung

NCT02037997 2016-02-23

Safety and Effectiveness Study of Chemotherapy in Combination With Erlotinib,or Sequential Erlotinib for Treatment in Patients With NSCLC

Carcinoma, Non-Small-Cell Lung

NCT02643407 2015-12-31

Nedaplatin/Docetaxel Versus Cisplatin/Docetaxel in Treatment of Advanced/Relapsed Squamous Cell Lung Cancer

488 enrolled

Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell

NCT01660399 2015-12-22

Clinical Trial of Boanmycin Hydrochloride With Docetaxel for Patients With Lung Squamous Cell Cancer as Chemotherapy

300 enrolled

Squamous Cell Lung Cancer

NCT01707329 2015-09-09

Icotinib in Combination With Chemotherapy Versus Chemotherapy Alone in Patients Progressed After Icotinib Treatment

180 enrolled